Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
Background: Retinopathy is a common adverse event with mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors. Little is known about the pathophysiology of MEK inhibitor-associated retinopathy (MEKAR). Since MEKAR has many similarities to central serous chorioretinopathy (CSCR), th...
Main Authors: | Andrew E. C. Booth, Ashley M. Hopkins, Andrew Rowland, Ganessan Kichenadasse, Justine R. Smith, Michael J. Sorich |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-07-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920944359 |
Similar Items
-
Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
by: Jessie Villanueva, et al.
Published: (2013-09-01) -
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
by: Sarah J. Welsh, et al.
Published: (2015-03-01) -
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
by: Clare Judith Stones, et al.
Published: (2013-05-01) -
Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib
by: Gavric Ana Ursula, et al.
Published: (2018-01-01) -
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
by: Zeynep Eroglu, et al.
Published: (2016-01-01)